Clinical trial registry record

The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 20, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06208527
Last registry update
January 20, 2025
Status
Recruiting
Phase
Phase 2
Sponsor
Haukeland University Hospital
Enrollment
100
Countries
Norway
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
100
Population
ALL · 75 Years
Duration
2025-01-01 to 2030-12-01
Intervention
Nicotinamide Riboside (NR); Placebo
Comparator
Placebo group
Outcomes measured
The between-group (NR vs. Placebo) difference in the change in gait speed. — 52 weeks; Incidence of treatment-emergent adverse events (safety and tolerability). — 52 weeks; Change in physical performance assessed by the Short Physical Performance Battery (SPPB). — 52 weeks; Change in physical performance assessed by hand grip strength. — 52 weeks; Change in cognitive function assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBA…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • NAD metabolism · 100%Title contains controlled term: nicotinamide riboside. Abstract contains controlled term: nicotinamide riboside. Source terminology contains: nicotinamide riboside. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

nad metabolism
Open primary sourceExport JSON